ArticleOncology letters2026
Integrated analysis identified MARK4 as a prognostic and immunomodulatory biomarker in oral squamous cell carcinoma.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral squamous cell carcinoma (OSCC) is the most common malignancy of the oral cavity and is characterized by high invasiveness and a poor prognosis. Although a number of molecular biomarkers have been investigated, their clinical applications remain limited. Despite microtubule affinity-regulating kinase 4 (MARK4) having been implicated in a number of cancers, its role in OSCC remains unclear. RNA-sequencing data and corresponding clinical information for patients with OSCC were obtained from The Cancer Genome Atlas database. MARK4 expression levels were analyzed in OSCC and corresponding noncancerous tissues. Associations between MARK4 expression and clinicopathological characteristics and survival outcomes, including overall survival (OS), disease-specific survival (DSS) and progression-free interval (PFI), were evaluated using univariate Cox regression and Kaplan-Meier analyses. Immune infiltration was assessed using single-sample Gene Set Enrichment Analysis, Cell-type Identification by Estimating Relative Subsets of RNA Transcripts and Tumor Immune Estimation Resource 2.0 analyses. To evaluate its functional role, two independent small interfering RNA was used to silence MARK4 expression in human squamous carcinoma-3 (HSC-3) cells. Results indicated that MARK4 was notably upregulated in OSCC and was associated with advanced T and clinical stages. High MARK4 expression was associated with poorer OS, DSS and PFI in the unadjusted survival analyses and showed discriminatory ability between tumor and normal tissues (area under the curve=0.841). Functional enrichment analysis indicated that MARK4 and its co-expressed genes were mainly involved in cytoskeletal organization, immune response and metabolic pathways. Immune infiltration analysis showed that MARK4 expression was negatively correlated with CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.